PDA
Pentadecapeptide Arginate — BPC-157 Arginate Salt
What is PDA?
PDA (Pentadecapeptide Arginate, also called BPC-157 Arginate or BPC-157 Stable) is the arginate salt form of BPC-157. The arginate modification dramatically improves oral bioavailability by increasing resistance to gastric acid degradation — making it the preferred form for gut-targeted applications where oral rather than injectable delivery is desired.
PDA retains all the biological mechanisms of BPC-157 — VEGF upregulation, angiogenesis, anti-inflammatory signaling, and gut healing — while surviving the gastrointestinal environment that rapidly degrades standard BPC-157 acetate. The arginate salt form creates a protective ionic environment around the peptide that stabilizes it through the acidic stomach environment before absorption in the small intestine.
Research Evidence
Arginate modification significantly improves oral stability and bioavailability vs standard BPC-157 acetate. The mechanism of acid protection is well-characterized.
In animal models of IBD, colitis, and gut injury, oral BPC-157 arginate shows healing effects consistent with injectable BPC-157 acetate, supporting the oral bioavailability claim.
Growing use in IBD, leaky gut, GERD, and gut motility protocols. Preferred over injectable BPC-157 for gut-specific applications by practitioners who prefer oral delivery.
Evidence grades: Gold = RCT human data · Silver = consistent animal/human data · Bronze = limited or preliminary
Dosing Protocols
Reconstitution Guide
| Vial Size | BAC Water | Concentration | Target draw |
|---|---|---|---|
| 10 mg | 10 ml | 1 mg/ml | 250mcg = 25 units (oral solution) |
| 20 mg | 20 ml | 1 mg/ml | 500mcg = 50 units (oral solution) |
Frequently Asked Questions
Is PDA the same as BPC-157?
PDA is the arginate salt form of BPC-157. The peptide sequence is identical — the difference is the salt form, which improves oral stability. For injectable use, BPC-157 acetate is the standard. For oral gut-targeted use, arginate (PDA) is preferred because it survives gastric acid that would degrade acetate.
Should I use PDA or injectable BPC-157 for gut healing?
For gut-specific conditions (IBD, leaky gut, GERD, colitis), oral PDA is often preferred — it delivers BPC-157 directly to the gut mucosa during absorption. For systemic effects or injury healing, injectable BPC-157 acetate is more effective. Many gut healing protocols use both: oral PDA for direct gut delivery and injectable acetate for systemic support.
References
- [1]Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632.
- [2]Sikiric P, Hahm KB, Blagaic AB, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut Liver. 2020;14(2):153-167.
This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.
Share this article